B-cell-mediated autoimmune diseases
Stories
-
Antengene announces first patient dosed in Phase I ATTRACT study of ATG-201
The company announced dosing began on Nov. 5, 2026 in China. The study is being conducted in China and Australia, and ATG-201 has received Human Research Ethics Committee approval in Australia and completed the Clinical Trial Notification process with the Therapeutic Goods Administration.